Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer

References

• De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23:3189 - 99; http://dx.doi.org/10.1038/sj.onc.1207545; PMID: 15094768
   PubMed Web of Science ®Google Scholar
• Goodfellow IG, Roberts LO. Eukaryotic initiation factor 4E. Int J Biochem Cell Biol 2008; 40:2675 - 80; http://dx.doi.org/10.1016/j.biocel.2007.10.023; PMID: 18069043
   PubMed Web of Science ®Google Scholar
• Thumma SC, Kratzke RA. Translational control: a target for cancer therapy. Cancer Lett 2007; 258:1 - 8; http://dx.doi.org/10.1016/j.canlet.2007.08.022; PMID: 17923280
   PubMed Web of Science ®Google Scholar
• Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003; 20:265 - 73; http://dx.doi.org/10.1023/A:1022943419011; PMID: 12741684
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68:631 - 4; http://dx.doi.org/10.1158/0008-5472.CAN-07-5635; PMID: 18245460
   PubMed Web of Science ®Google Scholar
• Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004; 23:3180 - 8; http://dx.doi.org/10.1038/sj.onc.1207544; PMID: 15094767
   PubMed Web of Science ®Google Scholar
• Rosenwald IB, Hutzler MJ, Wang S, Savas L, Fraire AE. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 2001; 92:2164 - 71; http://dx.doi.org/10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; PMID: 11596034
   PubMed Web of Science ®Google Scholar
• Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002; 8:3046 - 53; PMID: 12374671
   PubMed Web of Science ®Google Scholar
• Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ, Swain SM. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 2007; 17:281 - 7; PMID: 17203162
   PubMed Web of Science ®Google Scholar
• Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen LB. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer 2009; 66:237 - 44; http://dx.doi.org/10.1016/j.lungcan.2009.02.001; PMID: 19261348
   PubMed Web of Science ®Google Scholar
• Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y, et al. Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer 2010; 70:329 - 34; http://dx.doi.org/10.1016/j.lungcan.2010.03.006; PMID: 20621385
   PubMed Web of Science ®Google Scholar
• Khoury T, Alrawi S, Ramnath N, Li Q, Grimm M, Black J, et al. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 2009; 10:58 - 66; http://dx.doi.org/10.3816/CLC.2009.n.009; PMID: 19289374
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14:2895 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-2248; PMID: 18483355
   PubMed Web of Science ®Google Scholar
• Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332 - 7; http://dx.doi.org/10.1038/nature02369; PMID: 15029198
   PubMed Web of Science ®Google Scholar
• Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 2010; 29:1883 - 96; http://dx.doi.org/10.1038/onc.2009.479; PMID: 20101233
   PubMed Web of Science ®Google Scholar
• Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128:257 - 67; http://dx.doi.org/10.1016/j.cell.2006.11.046; PMID: 17254965
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007; 117:2638 - 48; http://dx.doi.org/10.1172/JCI32044; PMID: 17786246
   PubMed Web of Science ®Google Scholar
• Graff JR, Boghaert ER, De Benedetti A, Tudor DL, Zimmer CC, Chan SK, et al. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer 1995; 60:255 - 63; http://dx.doi.org/10.1002/ijc.2910600221; PMID: 7829225
   PubMed Web of Science ®Google Scholar
• Sun SY, Kurie JM, Yue P, Dawson MI, Shroot B, Chandraratna RA, et al. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer Res 1999; 5:431 - 7; PMID: 10037194
   PubMed Web of Science ®Google Scholar
• Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004; 64:9027 - 34; http://dx.doi.org/10.1158/0008-5472.CAN-04-3703; PMID: 15604268
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Wang Y, Wang T, Du ZY, Xu YJ, Lu YL. Differentially expressed genes in human giant-cell lung cancer lines with different metastatic potentials. Zhonghua Zhong Liu Za Zhi 2004; 26:590 - 3; PMID: 15634517
   PubMedGoogle Scholar
• Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997; 57:4931 - 9; PMID: 9354460
   PubMed Web of Science ®Google Scholar
• Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008; 7:1952 - 8; http://dx.doi.org/10.4161/cbt.7.12.6944; PMID: 18981735
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition. Cancer Res 2005; 65:7052 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-0917; PMID: 16103051
   PubMed Web of Science ®Google Scholar
• Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia 2010; 12:346 - 56; PMID: 20360945
   PubMed Web of Science ®Google Scholar
• Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR. The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells. J Biol Chem 2007; 282:18800 - 9; http://dx.doi.org/10.1074/jbc.M611438200; PMID: 17493934
   PubMed Web of Science ®Google Scholar